A Study of IRESSA in Relapsed and Refractory Small Cell Lung Cancer

• Status: Completed
• Trial end date: 2007-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the disease control rate at trial closure and after the first stage of the study in patients with relapsed or refractory SCLC and measurable disease treated with gefitinib

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Gefitinib

Criteria

Inclusion Criteria:

• Provision of written informed consent

• Histologically confirmed, relapsed or refractory SCLCr

• Aged 18 or over and a life expectancy of more than 2 months

Exclusion Criteria:

• Any evidence of clinically active interstitial lung disease

• Other co-existing malignancies or malignancies diagnosed within the last 5 years, with the exception of basal cell carcinoma or cervical cancer in situ.